J Korean Rheum Assoc.  2007 Jun;14(2):176-180. 10.4078/jkra.2007.14.2.176.

A Case of Pulmonary Hypertension in a Patient with Adult-onset Still's Disease

• Woo JH
• Chang SJ
• Yoo DH

• KMID: 1526437
• DOI: http://doi.org/10.4078/jkra.2007.14.2.176

Abstract

Pulmonary hypertension is one of the serious complications of autoimmune rheumatic disease, and it is becoming an important cause of morbidity and premature death. Pulmonary involvement occurs occasionally in adult-onset Still's disease (AOSD), but pulmonary hypertension has not been previously reported in Korea. We describe a 33-year-old woman with 5-year history of AOSD who presented with pulmonary hypertension, without evidences of pleural or parenchymal involvement of the lung, pulmonary embolism or any other obvious cause. Here, we report an AOSD patient with pulmonary hypertension with review of the literatures.

Keyword

Adult onset Still's disease (AOSD); Pulmonary hypertension

MeSH Terms

Adult
Female
Humans
Hypertension, Pulmonary*
Korea
Lung
Mortality, Premature
Pulmonary Embolism
Rheumatic Diseases
Still's Disease, Adult-Onset*

Figure

• 

  Fig. 1. Chest PA shows enlarged central pulmonary arteries.

• 

  Fig. 2. Transthorasic echocardiography shows D-shape left ventricular cavity.

Reference

1). Pouchot J., Sampalis JS., Beaudet F., Carette S., Decary F., Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine. 1991. 70:118–36.

2). Coghlan JG., Handler C. Connective tissue associated pulmonary arterial hypertension. Lupus. 2006. 15:138–42.

3). Mubashir E., Ahmed MM., Hayat S., Heldmann M., Berney SM. Pulmonary hypertension in a patient with adult-onset stills disease. Clin Rheumatol. 2006.

4). Zen A., Yamashita N., Ueda M., Asakawa Y., Yoshikawa Y., Funai T, et al. A case of adult Still's disease with pulmonary hypertension. Ryumachi. 1990. 30:45–52.

5). Magliano M., Isenberg DA., Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum. 2002. 46:1997–2009.

6). Tuder RM., Groves B., Badesch DB., Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994. 144:275–85.

7). Eddahibi S., Humbert M., Sediame S., Chouaid C., Partovian C., Maitre B, et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respi Crit Care Med. 2000. 162:1493–9.

8). Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995. 151:1628–31.

9). Shen JY., Chen SL., Wu YX., Tao RQ., Gu YY., Bao CD, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 1999. 18:147–51.

10). Dantzker DR. Primary pulmonary hypertension. The American experience. Chest. 1994. 105((Suppl):):26S–8S.

11). Rich S., Kaufmann E., Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New Engl J Med. 1992. 327:76–81.

12). Sanchez O., Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax. 1999. 54:273–7.

13). 최혜숙: 이상도. 폐동맥고혈압에서폐혈관계작용약물. 결핵및호흡기질환. 2006. 60:142–50.

14). Wilkens H., Guth A., Konig J., Forestier N., Cremers B., Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001. 104:1218–22.

15). Channick RN., Simonneau G., Sitbon O., Robbins IM., Frost A., Tapson VF, et al. Effects of the dual endo-thelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001. 358:1119–23.